Advanced search
Enter a research title, an expert name, a programme code such as ADSTEM, or a patent number such as 10-1172638. Results appear as cards with source links you can check yourself.
9 records for “ADSTEM”
Each record states the study stage, institution and source link.
phase2 · 2024
EHL BIO with five Korean hospitals including Chung-Ang University Hospital (as stated by the hospital)
The hospital's affiliated research centre states Phase 1 completed in 2017, Phase 2 completed in 2023 and a Phase 3 IND submitted in 2024. No accessible peer-reviewed results confirm efficacy, and this is not approved treatment in Thailand.
EHL BIO (research page)phase1-2 · 2024
Multiple institutions (indexed in PubMed)
Small studies report reduced severity scores in some patients; better-controlled studies are needed for confirmation.
PubMedphase1 · 2023
EHL BIO (Korea)
The hospital's affiliated research centre states IND approval and Phase 1 initiation in 2023, with selection for the KFRM programme in 2022 and 2024. A Phase 1 trial targets safety, not proof of efficacy.
EHL BIO (research page)preclinical · 2024
EHL BIO (Korea)
The hospital's affiliated research centre states the programme is at non-clinical stage, so there are no efficacy or safety data in people with Parkinson's disease, and it is not approved treatment.
EHL BIO (research page)Titles listed on EHL BIO's research institute page, with PubMed lookup links.
19 Nov 2016
6 Nov 2018
A patent evidences intellectual-property registration, not treatment efficacy.
No. 10-2016-0139967
Registered 26 Oct 2016
Pharmaceutical composition for preventing or treating atopic disease, using cells cultured with a 15-PGDH inhibitor in PGE2-expressing cells or their culture (atopic dermatitis).
EHL BIO patent pageNo. 10-2018-0030906
Registered 16 Mar 2018
Pharmaceutical composition for preventing or treating atopic disease (atopic dermatitis).
EHL BIO patent pagePublished profiles contain only details checkable against public sources.
EHL BIO
Stem cell therapeutics research and development team
ADSTEM (atopic dermatitis), KDSTEM (chronic kidney disease), RASTEM (rheumatoid arthritis), PDSTEM (Parkinson's disease) and adipose-derived exosome programmes
EHL BIO — Stem cell treatmentAn EHL doctor or scientist? Submit your real biography and licence for the register.
Submit expert profile